drugset / Trial / NCT00983385

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics

NCT00983385

Phase 3 Completed 208 enrolled Grünenthal GmbH
NaSingle-groupOpen-labelTreatment

Summary

The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release in subjects suffering from severe chronic low back pain (LBP) who are taking either WHO Step I or Step II analgesics or no regular analgesics. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome. The trial will compare the effectiveness of previous analgesic treatment (either WHO Step I or Step II analgesics or no regular analgesics) with that of tapentadol hydrochloride prolonged release (PR) treatment during defined periods of evaluation.

Timeline

Start
2009-09-30
Primary completion
2010-05
Completion
2010-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tapentadol Small molecule 50 mg Oral
Subject Tapentadol Small molecule 100 mg Oral
Subject Tapentadol Small molecule 150 mg Oral
Subject Tapentadol Small molecule 200 mg Oral
Subject Tapentadol Small molecule 250 mg Oral

Indications